Rare metabolic disorders are caused due genetic conditions which result in metabolism problems. Defective gene present in individuals with metabolic disorder results in deficiency of essential enzymes.
Rare metabolic disorders are caused due genetic conditions which result in metabolism problems. Defective gene present in individuals with metabolic disorder results in deficiency of essential enzymes. There are several types of metabolic disorders with varied symptoms, diagnosis, and treatments. Gene mutation is the leading cause of rare metabolic disorders. The mutated gene is passed from one generation to another generation. This type of genetic transmission is known as autosomal recessive inheritance. The incidence rate of rare metabolic disorder in newborn population is about 1 in 1,000 to 2,500. The rate of inheritance of rare metabolic disorders in ethnic population such as Jews of Central and Eastern Europe is much higher. Rare metabolic disorders can be divided into disorders of carbohydrate metabolism, disorder of protein metabolism, and others.
Read Report Overview - https://www.transparencymarketresearch.com/rare-metabolic-disorders-screening-market.html
According to the European Federation of Pharmaceutical Industries and Associations, rare metabolic disorders such as Pompe’s disease affect approximately 5,000 to 10,000 people globally. Most affected babies die in their rest year of life. It is caused due to deficiency of the enzyme acid maltase and leads severe muscle degeneration of the heart and the lung. Fabry’s disease is estimated to occur in approximately 1 in 40,000 births and affects around 5,000 people. It is caused due to deficiency of enzyme alpha-galactosidase A, and leads to progressive accumulation of lipids in the kidney, heart, and other organs.
Inherited condition of type 1 mucopolysaccharidosis is another rare metabolic disorder affecting approximately 3,000 to 4,000 people globally. It is caused due alpha-L-iduronidase enzyme deficiency. Symptoms for this type of rare metabolic disorder are progressive damage to heart, lungs, liver, and kidneys, and in some cases neurological. The Hurler form is the most serious type which leads to severe neurological disorder, obstructive respiratory disease, and death before the age of ten. Scheie form, which is comparatively less severe, leads to corneal clouding, stiffness in joints, and heart disease.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20792
Diagnosis of rare metabolic disorders is generally carried out through blood screening by measurement of metabolic products which accumulate in the blood stream and urine. The identification process of these metabolites is carried out by using sophisticated chromatographic equipment. The treatment of rare metabolic disorders is generally carried out using enzyme replacement therapy. On February 08, 2017, the FDA approved the first new born screening system for rare metabolic disorders (mucopolysaccharidosis type I, Pompe, Gaucher, and Fabry) “The Seeker System” by Baebies Inc. According to the U.S. Department of Health and Human Services, these disorders are observed in approximately 1 in 5,000 to 1 in 185,000 children.
Request for Covid-19 Impact Analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=20792
Increasing awareness, rise in research activities in the field of proteomics and metabolomics, changing lifestyle, advancements in the health care industry, and technological advancement in biopharmaceuticals is expected to drive the rare metabolic disorder screening market during the forecast period. Rare metabolic disorder screening is gaining popularity among the new generation due to increasing awareness regarding genetic disorders which could prove to be life threatening. High cost of treatment, stringent government regulation, and unfavorable reimbursement act as restraints of the rare metabolic disorder screening market.
Geographically, the global rare metabolic disorder screening market has been segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America leads the global rare metabolic disease screening market because of increasing population, rising number of screening procedures, and technological advancements. It was closely followed by Europe and Asia Pacific. Asia Pacific is an emerging market for rare metabolic disorder disease screening primarily because of increasing health care expenditure in the region and growing awareness.
Pre Book Rare Metabolic Disorders Screening Market Report at - https://www.transparencymarketresearch.com/checkout.php?rep_id=20792<ype=S
Key players in the global rare metabolic disorder screening market are Baebies, Inc., Shire plc, BioMarin, Actelion Pharmaceuticals Ltd., Sanofi, Pfizer, Inc., GlaxoSmithKline, and Amicus Therapeutics, Inc., among others.
More Trending Reports by Transparency Market Research:
Therapeutic Proteins for Metabolic Disorders Treatment Market: Therapeutic proteins are proteins which are engineered in a laboratory for pharmaceutical use. Therapeutic proteins are used as a personalized treatment approach which supports a precisely targeted therapeutic process by making up for the deficiency of an essential protein.
Metabolic Testing Market: Metabolism is a set of chemical processes that takes place in a body to maintain its living state. Metabolic rates varies from person to person and depends upon the gender, height, weight, age, muscle to fat ratios, and the current physical rate of activity. Metabolic testing devices are used to find metabolic parameters. Metabolism involves a series of reactions in which a molecule is converted into a product with the help of enzymes.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/